Most Likely Condition: Acute Leukemia (Probable AML - Acute Myeloid Leukemia)

Key Findings That Point to This Diagnosis

• Hb dropped from 8.4 g/dL → 4.2 g/dL over 2.5 weeks
• This severe, rapidly worsening anemia is due to bone marrow replacement by blasts, crowding out normal erythropoiesis

• Platelets: 48,000 → 1,26,000 → 86,000 → 45,000
• Initial severe thrombocytopenia, brief reactive rise, then falling again - typical of marrow failure

• Marked leukocytosis with left-shifted granulopoiesis (immature myeloid cells)
• Atypical mononuclear cells
• Few myelocytes in the background
• Blastoid cells identified - immature precursor cells normally not seen in peripheral blood

• CRP 140.3 → 179.7 - significant systemic inflammation, not explained by typhoid (Widal -ve) or malaria (-ve)

• Suggests bone marrow infiltration or hepatic involvement by leukemia

• Reflects chronic illness, nutritional decline, and systemic disease burden

• Consistent with high cell turnover (tumor lysis physiology)

Why AML Over ALL?

Next Mandatory Workup

1. Bone Marrow Aspiration + Biopsy - confirm >20% blasts (WHO diagnostic threshold for acute leukemia)
2. Flow Cytometry / Immunophenotyping - distinguish ALL (CD10, CD19, TdT positive) vs AML (CD13, CD33, CD117, MPO positive)
3. Cytogenetics / FISH / Molecular studies - t(15;17) for APML, t(8;21), inv(16), Philadelphia chromosome, etc. - critical for prognosis and targeted therapy
4. LDH - marker of tumor burden (not documented here)
5. Coagulation profile (PT/APTT/D-dimer) - rule out DIC, especially if APML is suspected (very high Auer rod burden)

Important Note

Clinical Bottom Line: The combination of marked leukocytosis with blastoid cells on peripheral smear, severe progressive anemia, thrombocytopenia, negative infectious workup (typhoid -ve, malaria -ve), and a smear explicitly suspicious for "underlying hematological neoplasm" makes Acute Leukemia (likely AML) the primary diagnosis until proven otherwise by bone marrow biopsy.

Pediatric ALL vs AML: Latest Diagnostic Guidelines & Protocols (2024-2026)

Authoritative Sources Referenced

STEP 1: Establish the Diagnosis of Acute Leukemia

Mandatory Initial Workup

WHO-HEM5 threshold: ≥20% blasts in bone marrow or peripheral blood defines acute leukemia. Exception: certain genetic subtypes of AML (e.g. t(15;17), t(8;21), inv(16)) are diagnostic regardless of blast count. - Tembhare et al. (J Clin Pathol, 2025) [PMID: 40318860]

STEP 2: Lineage Determination - ALL vs AML

ALL (Lymphoblastic) - Immunophenotypic Markers

B-cell ALL (B-ALL) - ~85% of pediatric ALL

T-cell ALL (T-ALL) - ~15% of pediatric ALL

AML (Myeloid) - Immunophenotypic Markers

The 2026 International Pediatric AML Consensus ([PMID: 41105890]) emphasizes multimodal analysis - morphology + immunophenotyping + genetic testing together, not any single modality in isolation.

STEP 3: WHO 5th Edition Classification (2022/Applied 2025)

Pediatric AML - 3 Primary Categories (WHO-HEM5)

1. AML with defining genetic abnormalities - highest diagnostic/prognostic priority
   • AML with t(8;21) / RUNX1::RUNX1T1 - Favorable
   • AML with inv(16) / CBFB::MYH11 - Favorable
   • APL with t(15;17) / PML::RARA - Very favorable (treat as emergency, risk of DIC)
   • AML with KMT2A rearrangement - Poor
   • AML with NUP98 fusions - Poor (newly added in WHO-HEM5)
   • AML with mutated NPM1 - Intermediate-Favorable
   • AML with FLT3-ITD - High risk modifier
   • AML with mutated CEBPA - Favorable (biallelic)
2. AML defined by differentiation (FAB-morphology based, when no defining genetic lesion found)
   • M0-M7 morphologic subtypes
3. Myeloid neoplasms with predisposing conditions
   • Down syndrome-associated AML (GATA1 mutations, distinct pathway)
   • Germline predisposition syndromes (Fanconi anemia, RUNX1 germline, etc.)

Pediatric ALL - WHO-HEM5 Subtypes

• TAL1/TAL2, TLX1, TLX3, HOXA cluster, NKX2-1 rearrangements
• NOTCH1/FBXW7 mutations (favorable in T-ALL)
• Early T-cell precursor (ETP-ALL) - highest risk, distinct phenotype

STEP 4: Distinguishing Features in the Peripheral Smear

In this patient's case, the presence of myelocytes and left-shifted granulopoiesis on the peripheral smear strongly favors AML over ALL, though immunophenotyping is still mandatory.

STEP 5: Mixed Phenotype Acute Leukemia (MPAL) - Don't Miss It

• Accounts for 1-5% of acute leukemias
• Diagnosed when >20% blasts AND two lineages are simultaneously co-expressed
• WHO-HEM5 diagnostic criteria: MPO expression (myeloid) + CD19/CD22/CD10 (B-cell) co-expressed in same blast population
• B/Myeloid MPAL is most common (59%), T/Myeloid is next (35%)
• Treatment: ALL-based regimens show superior CR rates; HSCT if CR achieved

STEP 6: Risk Stratification After Diagnosis

Pediatric ALL Risk Groups (Standard per COG/BFM protocols)

Pediatric AML Risk Groups (2026 International Consensus [PMID: 41105890])

STEP 7: Minimal Residual Disease (MRD) - Now Central to Management

• Pediatric AML: Post-induction MRD by multiparameter flow cytometry (MFC) at threshold <0.1% (or <0.05% in some protocols). MRD negativity = preferred endpoint; MRD positivity is an independent adverse predictor of event-free survival. - 2026 Consensus [PMID: 41105890]
• Pediatric ALL: MRD at Day 15 (interim), Day 29 (end-induction), Day 43-78 (end-consolidation) guides therapy escalation/de-escalation. MRD by flow cytometry or PCR.

Quick Reference: Key Markers at a Glance

SUSPECT LEUKEMIA (blasts on smear + pancytopenia)
         ↓
   BONE MARROW ASPIRATION
         ↓
   Flow Cytometry (Immunophenotyping)
         ↓
   ┌─────────────────────────────────────────┐
   │ MPO+ / CD13+ / CD33+ / CD117+  → AML   │
   │ TdT+ / CD19+ / CD10+           → B-ALL │
   │ TdT+ / CD3+ / CD7+             → T-ALL │
   │ Both myeloid + lymphoid markers → MPAL  │
   └─────────────────────────────────────────┘
         ↓
   Cytogenetics + FISH + Molecular Panel
         ↓
   Risk Stratification → Treatment Protocol
         ↓
   MRD Monitoring (Day 15/29 for ALL; post-induction for AML)

For This Patient Specifically